{"id":15046,"date":"2019-09-09T18:05:25","date_gmt":"2019-09-09T16:05:25","guid":{"rendered":"https:\/\/www.hollandbio.nl\/?p=15046"},"modified":"2019-09-10T18:16:06","modified_gmt":"2019-09-10T16:16:06","slug":"glycostem-raises-capital-for-phase-i-iia-clinical-trials","status":"publish","type":"post","link":"https:\/\/www.hollandbio.nl\/en\/nieuws\/glycostem-raises-capital-for-phase-i-iia-clinical-trials\/","title":{"rendered":"Glycostem raises capital for phase I\/IIa clinical trials"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Glycostem Therapeutics, a clinical stage and leading NK-cell company today announced that Korean investor, E&amp;F Healthcare Holdings and existing investor LUPUS Ventures B.V.  have invested \u20ac9 million and \u20ac5 million respectively. Together with the recently announced \u20ac5 million awarded by the Dutch Government (RVO\u2019s Innovation Credit grant plus various commercial revenues from development partners; Glycostem has funding for the duration of the phase I\/IIa trial for its lead product oNKord\u00ae in the indications of AML and MM. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Troels Jordansen, CEO said <em>\u201cThis funding allows us to progress the clinical development of our unique and exciting lead product; oNKord\u00ae. It is also a significant step in the treatment with offthe-shelf, cellular immunotherapy products in hard-to-treat cancer patients. We would like to welcome E&amp;F Healthcare Holdings as a shareholder. It is the second time LUPUS invests in Glycostem and we are very proud and honour to be working with these two uniquely dynamic shareholders. Since the first investment by LUPUS, Glycostem has met its objectives, reached the milestones and is advancing according to plan. The GMP license (announced 25th June \u201819) will facilitate production of oNKord\u00ae for the phase I\/IIa clinical trials for our lead product oNKord\u00ae in AML starting early \u201920, followed by MM indication 12 months later, is a good example of how fast we have advanced. We have, however, also made great advances on cell yield, automation and setting up our own CAR-NK products.\u201d<\/em> <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Source: <strong><a href=\"http:\/\/glycostem.com\/_cache\/glycostem\/media\/ftvnp93083\/190909_Funding_update.pdf\">Glycostem<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Glycostem Therapeutics, a clinical stage and leading NK-cell company today announced that Korean investor, E&amp;F Healthcare Holdings and existing investor LUPUS Ventures B.V. have invested \u20ac9 million and \u20ac5 million respectively. Together with the recently announced \u20ac5 million awarded by the Dutch Government (RVO\u2019s Innovation Credit grant plus various commercial revenues from development partners; Glycostem [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[43],"tags":[],"class_list":["post-15046","post","type-post","status-publish","format-standard","hentry","category-innovatieklimaat"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Glycostem raises capital for phase I\/IIa clinical trials - hollandbio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/glycostem-raises-capital-for-phase-i-iia-clinical-trials\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Glycostem raises capital for phase I\/IIa clinical trials - hollandbio\" \/>\n<meta property=\"og:description\" content=\"Glycostem Therapeutics, a clinical stage and leading NK-cell company today announced that Korean investor, E&amp;F Healthcare Holdings and existing investor LUPUS Ventures B.V. have invested \u20ac9 million and \u20ac5 million respectively. Together with the recently announced \u20ac5 million awarded by the Dutch Government (RVO\u2019s Innovation Credit grant plus various commercial revenues from development partners; Glycostem [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/glycostem-raises-capital-for-phase-i-iia-clinical-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"hollandbio\" \/>\n<meta property=\"article:published_time\" content=\"2019-09-09T16:05:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-09-10T16:16:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"hollandbio\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:site\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hollandbio\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/glycostem-raises-capital-for-phase-i-iia-clinical-trials\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/glycostem-raises-capital-for-phase-i-iia-clinical-trials\\\/\"},\"author\":{\"name\":\"hollandbio\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/833d6a25b39946e61c6101af1fa96fbb\"},\"headline\":\"Glycostem raises capital for phase I\\\/IIa clinical trials\",\"datePublished\":\"2019-09-09T16:05:25+00:00\",\"dateModified\":\"2019-09-10T16:16:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/glycostem-raises-capital-for-phase-i-iia-clinical-trials\\\/\"},\"wordCount\":248,\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"articleSection\":[\"Innovatieklimaat\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/glycostem-raises-capital-for-phase-i-iia-clinical-trials\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/glycostem-raises-capital-for-phase-i-iia-clinical-trials\\\/\",\"name\":\"Glycostem raises capital for phase I\\\/IIa clinical trials - hollandbio\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\"},\"datePublished\":\"2019-09-09T16:05:25+00:00\",\"dateModified\":\"2019-09-10T16:16:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/glycostem-raises-capital-for-phase-i-iia-clinical-trials\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/glycostem-raises-capital-for-phase-i-iia-clinical-trials\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/glycostem-raises-capital-for-phase-i-iia-clinical-trials\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Glycostem raises capital for phase I\\\/IIa clinical trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"name\":\"hollandbio\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\",\"name\":\"hollandbio\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"width\":218.664,\"height\":29.659,\"caption\":\"hollandbio\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/hollandbio\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/hollandbio\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/833d6a25b39946e61c6101af1fa96fbb\",\"name\":\"hollandbio\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Glycostem raises capital for phase I\/IIa clinical trials - hollandbio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.hollandbio.nl\/en\/nieuws\/glycostem-raises-capital-for-phase-i-iia-clinical-trials\/","og_locale":"en_US","og_type":"article","og_title":"Glycostem raises capital for phase I\/IIa clinical trials - hollandbio","og_description":"Glycostem Therapeutics, a clinical stage and leading NK-cell company today announced that Korean investor, E&amp;F Healthcare Holdings and existing investor LUPUS Ventures B.V. have invested \u20ac9 million and \u20ac5 million respectively. Together with the recently announced \u20ac5 million awarded by the Dutch Government (RVO\u2019s Innovation Credit grant plus various commercial revenues from development partners; Glycostem [&hellip;]","og_url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/glycostem-raises-capital-for-phase-i-iia-clinical-trials\/","og_site_name":"hollandbio","article_published_time":"2019-09-09T16:05:25+00:00","article_modified_time":"2019-09-10T16:16:06+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png","type":"image\/png"}],"author":"hollandbio","twitter_card":"summary_large_image","twitter_creator":"@hollandbio","twitter_site":"@hollandbio","twitter_misc":{"Written by":"hollandbio","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/glycostem-raises-capital-for-phase-i-iia-clinical-trials\/#article","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/glycostem-raises-capital-for-phase-i-iia-clinical-trials\/"},"author":{"name":"hollandbio","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/833d6a25b39946e61c6101af1fa96fbb"},"headline":"Glycostem raises capital for phase I\/IIa clinical trials","datePublished":"2019-09-09T16:05:25+00:00","dateModified":"2019-09-10T16:16:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/glycostem-raises-capital-for-phase-i-iia-clinical-trials\/"},"wordCount":248,"publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"articleSection":["Innovatieklimaat"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/glycostem-raises-capital-for-phase-i-iia-clinical-trials\/","url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/glycostem-raises-capital-for-phase-i-iia-clinical-trials\/","name":"Glycostem raises capital for phase I\/IIa clinical trials - hollandbio","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/#website"},"datePublished":"2019-09-09T16:05:25+00:00","dateModified":"2019-09-10T16:16:06+00:00","breadcrumb":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/glycostem-raises-capital-for-phase-i-iia-clinical-trials\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.hollandbio.nl\/en\/nieuws\/glycostem-raises-capital-for-phase-i-iia-clinical-trials\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/glycostem-raises-capital-for-phase-i-iia-clinical-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.hollandbio.nl\/en\/"},{"@type":"ListItem","position":2,"name":"Glycostem raises capital for phase I\/IIa clinical trials"}]},{"@type":"WebSite","@id":"https:\/\/www.hollandbio.nl\/en\/#website","url":"https:\/\/www.hollandbio.nl\/en\/","name":"hollandbio","description":"","publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.hollandbio.nl\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.hollandbio.nl\/en\/#organization","name":"hollandbio","url":"https:\/\/www.hollandbio.nl\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","contentUrl":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","width":218.664,"height":29.659,"caption":"hollandbio"},"image":{"@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/hollandbio","https:\/\/www.linkedin.com\/company\/hollandbio\/"]},{"@type":"Person","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/833d6a25b39946e61c6101af1fa96fbb","name":"hollandbio"}]}},"_links":{"self":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/15046","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/comments?post=15046"}],"version-history":[{"count":0,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/15046\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/media?parent=15046"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/categories?post=15046"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/tags?post=15046"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}